Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BioSyent’s (RX) board adopts advance notice by-law
  • The By-law establishes a framework for providing advance notice to BioSyent in circumstances
  • The By-law fixes deadlines by which shareholders of record of BioSyent must submit director nominations to BioSyent prior to any annual or special meeting of shareholders
  • Deadline for notice to BioSyent pursuant to the By-law is not less than 30 days prior to the date of the annual meeting
  • BioSyent Inc. (RX) is in the grey, trading at C$8.08 at 11:17 am EST

BioSyent Inc. (RX) Board of Directors has approved the adoption of an advance notice by-law.

This by-law will serve several purposes including:

  • Facilitating an orderly and efficient annual general or, where the need arises, special meeting process.
  • Ensuring that all shareholders of the company receive adequate notice of nominations for the Board of Directors of the company and sufficient information regarding all director nominees.
  • Allowing shareholders to register an informed vote after having been afforded reasonable time for appropriate deliberation.

The advance notice by-law establishes a framework for providing advance notice to BioSyent in circumstances where nominations of persons for election to the Board of Directors are put forward by BioSyent shareholders.

The By-law fixes deadlines by which shareholders of record of BioSyent must submit director nominations to BioSyent prior to any annual or special meeting of shareholders and sets forth the information a shareholder must include in the notice to BioSyent for an effective nomination to occur.

No person will be eligible for election as a director of BioSyent unless nominated in accordance with the provisions of the by-law.

In the case of an annual meeting of shareholders, the deadline for notice to BioSyent pursuant to the by-law is not less than 30 days prior to the date of the annual meeting of shareholders.

The By-law is effective immediately and will be placed before shareholders for approval, confirmation and ratification at the company’s next annual general and special meeting of shareholders.

BioSyent is a profitable, growth-oriented, specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.

BioSyent Inc. (RX) is in the grey, trading at C$8.08 at 11:17 am EST.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.